



HAL
open science

Antitumour necrosis factor- α therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013

E. Sbidian, C. Hotz, J. Seneschal, A. Maruani, F. Amelot, F. Aubin, C. Paul, M. Beylot Barry, P. Humbert, A. Dupuy, et al.

► To cite this version:

E. Sbidian, C. Hotz, J. Seneschal, A. Maruani, F. Amelot, et al.. Antitumour necrosis factor- α therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013. *British Journal of Dermatology*, 2016, 174 (3), pp.667-670. 10.1111/bjd.14199 . hal-01207284

HAL Id: hal-01207284

<https://univ-rennes.hal.science/hal-01207284v1>

Submitted on 13 Jan 2016

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Accepted Date : 14-Sep-2015

Anti-TNF α therapy for hidradenitis suppurativa. Results from a national cohort study between 2000 and 2013

E. Sbidian,^{1,2,3*} C. Hotz,^{1*} J. Seneschal,⁴ A. Maruani,⁵ F. Amelot,⁶ F. Aubin,⁷ C. Paul,⁶ M. Beylot Barry,⁸ P. Humbert,⁹ A. Dupuy,¹⁰ F. Caux,¹¹ N. Dupin,¹² P. Modiano,¹³ P. Lepasant,¹³ S. Ingen-Housz-Oro,^{1,3} E. Mahé,¹⁴ H. Bachelez,¹⁵ O. Chosidow,^{1,2,3*} P. Wolkenstein,^{1,3*}

*equally contributed

¹AP-HP, Hôpitaux universitaires Henri Mondor, Département de Dermatologie, UPEC, Créteil, F-94010, France;

²Inserm, Centre d'Investigation Clinique 1430, Créteil, F-94010, France;

³EA EpidermE, Université Paris-Est Créteil, UPEC, Créteil, F-94010, France;

⁴Hôpital Saint-André, Département de Dermatologie, Centre de référence des maladies cutanées rares; INSERM U1035, Université de Bordeaux, Bordeaux, F-33000, France;

⁵Hôpitaux universitaires de Tours, Hôpital Trousseau, Université François Rabelais, Service de Dermatologie, Tours, F-37000, France;

⁶Hôpitaux universitaires de Toulouse, Département de Dermatologie; Université Paul Sabatier, UMR CNRS 5165, INSERM 1056, Toulouse, F-31000, France;

⁷Université de Franche Comté, EA 3181, SFR4234; Centre Hospitalier Universitaire, Département de Dermatologie, Besançon, F-25000, France;

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/bjd.14199

⁸Centre Hospitalier Universitaire, Hôpital du Haut Lévêque, Département de Dermatologie, Université de Bordeaux EA 2406, Pessac, F-33600, France;

⁹Université de Franche Comté, INSERM U1098, SFR4234; Centre Hospitalier Universitaire, Département de Dermatologie, Besançon, F-25000, France;

¹⁰Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, Département de Dermatologie; Inserm CIC 1414, Université de Rennes 1, Rennes, F-35000, France;

¹¹AP-HP, Hôpitaux Universitaires Avicenne, Département de Dermatologie; Centre de Référence MAGEC ; Université Paris 13, Bobigny, F-93000, France;

¹²AP-HP, Hôpitaux Universitaires Cochin, Département de Dermatologie; Université Paris Descartes Paris V, Paris, F-75014, France;

¹³GHICL, Hôpital Saint-Vincent-de-Paul, Département de Dermatologie, Lille, F-59000, France;

¹⁴Hôpital Victor Dupouy, Département de Dermatologie, Argenteuil, F-95100, France

¹⁵Sorbonne Paris Cité Université Paris Diderot; Service de Dermatologie, AP-HP Hôpital Saint-Louis, Paris, F-75010 France;

Corresponding author: Emilie Sbidian, Service de Dermatologie, Hôpital Henri Mondor, 51 av du Maréchal de Lattre de Tassigny, F-94010, Créteil, France, Tel: 00 33 1 49 81 25 01, Fax: 00 33 1 49 81 25 08, emilie.sbidian@aphp.fr

Funding sources : none

Conflict of interest statement: E Sbidian, C Hotz, O Chosidow, A Maruani, F Amelot, P Lepasant, S Ingen-Housz-Oro, J Seneschal, N Dupin and P Humbert have no conflict of interest.

E. Mahé is a consultant for Abbvie, and Pfizer; has been investigator for Pfizer, and Abbvie; and has received speaker honoraria from Abbvie, and Pfizer; H Bachelez had consulting activities for Abbvie, Amgen, Boehringer, Celgene, Lilly, Janssen, MSD, Novartis, Pfizer, Takeda; Pierre Fabre, Sandoz; C Paul had consulting activities for Abbvie, Amgen, Celgene, Janssen, Leo Pharma, Novartis; F Aubin had consulting activities for Merck Serono, MSD/Schering-Plough, Pfizer, Abbvie, Janssen, Galderma, Leo Pharma, Novartis, Astellas, La Roche Posay; M Beylot Barry had consulting activities for Janssen, Abbvie, Pfizer, Lilly, Celgene, Leo Pharma, Novartis, MSD; F Caux had received speaker honoraria from Abbvie; P Wolkenstein had consulting activities for Abbvie, Pierre Fabre, Laboratoire Expanscience; A Dupuy had consulting activities for MSD, Pierre Fabre, P Modiano had consulting activities for Abbvie and LeoPharma.

To the editor

Hidradenitis suppurativa (HS) is a frequent chronic inflammatory skin disease typically characterized by recurrent painful, deep inflammatory nodules of the axillary, breast, groin and gluteal areas.^{1,2} European recommendations are mainly based on expert opinion³. Drug treatments are heterogenous (e.g., antibiotics, corticosteroids, retinoids) and lack consensus among expert centres.³ The most severe disease forms or those failing to respond to conventional drugs may be associated with worsened functional prognosis. Anti-tumor necrosis factor α (anti-TNF α) drugs have been prescribed in these cases. The results of randomized controlled trials (RCTs) are discordant. Three RCTs concluded to the efficacy of adalimumab (ADA),⁴⁻⁶ and two others did not detect any difference between infliximab (IFX) or etanercept (ETA) and placebo.^{7,8} Finally, data from the literature and reported experiences do not conclude on the efficacy of anti-TNF α drugs for HS.

The aim of this study was to assess the efficacy of anti-TNF α drugs in patients with HS seen in routine care.

We conducted a national retrospective cohort. Patients who presented HS and who received at least one anti-TNF α drug during the evolution of the disease were eligible. We contacted 25 centres,

This article is protected by copyright. All rights reserved.

including mainly teaching hospitals (n=22) but also general hospitals (n=3). Eleven had eligible patients, 7 had no eligible patients and the 7 other centres did not respond to our requests. For each centre with eligible patients, patients were selected by a cross-examination of data from January 1, 2000 to December 31, 2013 in 3 databases (the dermatology department databases, the national database in France PMSI, Programme de Médicalisation des Systèmes d'Information and the hospital pharmacy databases). Duplicates were excluded.

A standardized form was used to record sociodemographic characteristics. Associated inflammatory diseases were also recorded, as was personal history of HS. Anatomic zones involved at least once in the history of the patient were classified as breast and armpit, follicular and gluteal involvement.⁹ Disease severity was evaluated at the time of clinical examination by the Hurley grade. Details of the anti-TNF α therapy recorded included the molecule, dosage, treatment duration, and adverse effects.

Patients were classified into 3 groups of response after first-line anti-TNF α treatment: (1) complete response (resolution of all skin lesions or at least 90% improvement), (2) partial response (at least 50% improvement), and (3) no response. Event-free survival was measured from the date of the beginning of anti-TNF α treatment to the date of the first relapse or lost to follow-up. The factors that could influence progression-free survival times were tested with Cox's proportional hazards model.

Among 18 centres, we identified 67 patients with HS (37 [55.2%] women; median age 38.0 years (range 10.9–71.8 years) who received an anti-TNF α drug during this 13-year period. Characteristics of the study population are in Table 1. The most frequent anti-TNF α drug prescribed as first-line treatment was IFX, 5 mg/kg (n=57/66, 86.4%), then ADA, 40 mg every 2 weeks (n=7/66, 10.6%) and ETA, 50 mg twice a week (n=2/66, 3.0 %). The median follow-up was 6.8 months [interquartile range (IQR) 3.6–19.1]. Eight cases (11.9%) achieved complete response, 31 (46.2%) partial response and 25 (37.3%) no response, 3 (4.6%) had just been treated by anti-TNF α drugs and

Accepted Article

monitoring data were not available. The median follow-up for the 3 groups was 22.8 [10.4–44.2], 13.2 [4.7–22.9] and 4.6 [1.4–7.9] months, respectively. Twelve patients (17.9%) received 2 anti- TNF α drugs and 5 (7.4%), 3.

Factors associated with a complete or at least a partial response to first line anti-TNF α therapy in univariate and multivariate analysis are summarized Table 2. On multivariate analysis, complete response to first line anti-TNF α therapy was independently associated with currently smoking (hazard ratio [HR] 8.4, 95% confidence interval 1.3–56.0; p=0.03) and associated inflammatory bowel or arthritis diseases (HR 6.8, 1.2–40.0; p=0.03). Only one patient with an inflammatory arthritis disease who achieved complete response had received another immunosuppressive treatment (methotrexate). Partial response to first line anti-TNF α therapy was associated with only ADA treatment (HR 6.6, 2.2–19.7), p=0.001). In total, 5/7 patients (71.4%) receiving ADA achieved a partial response and none receiving ADA had a complete response. Four patients had to stop anti-TNF α treatment because of severe side effects (1 case each of hepatitis, lupus, repeated urinary tract infection, and pulmonary embolism).

Our results suggest modest and inconsistent efficacy of anti-TNF α therapy for moderate to severe HS. Complete and persistent clinical responses were rarely obtained (11.9%) and partial response was achieved in 46.2% of patients. These results are consistent with a retrospective Spanish cohort study of 19 patients.¹⁰ Anti-TNF α therapy could be efficient in this subset of patients presenting an associated inflammatory disorder.

Currently smoking was an independent factor associated with a complete response to anti-TNF α therapy. These results are contrary to data provided by registers dealing with inflammatory arthritis.¹¹ However, previous reports had suggested that smokers, particularly those who smoked before the HS, had a less severe form of HS than never-smokers.¹² In addition, current smoking is a protective factor in other inflammatory diseases such as ulcerative colitis.¹³ Larger studies are needed to better determine the protective effect of tobacco use in patients with HS.

Accepted Article

Finally, partial response to anti-TNF α therapy was about 7 times higher for patients who received ADA as compared with ETA or IFX. This result highlights a possible class effect of ADA and agrees with results of other RCTs and the recent approval of ADA (40 mg weekly after initial doses of 160 mg at week 0 and 80 mg at week 2) as a possible treatment for patients with active moderate to severe HS by the European Medicines Agency (EMA).^{4-6,14} Higher dosages of ADA as mentioned above might be associated with higher response rates as compared with a standard dosage (40 mg every 2 weeks).⁵ All patients of our cohort received the standard dosage which could have undermined the overall response rate.

To conclude, anti-TNF α therapy in patients with moderate to severe HS seems more efficient in a subset of patients with associated arthritis or inflammatory bowel disorder. Complete and persistent clinical response, with anti-TNF α drugs used as a single agent, was rarely obtained. ADA seems to be more efficient than IFX and ETA. Other therapeutic strategies, such as anti-TNF α drugs especially higher dosages of ADA used before surgery or low dose methotrexate in combination, have yet to be assessed.

Acknowledgements

The authors are indebted to Laura Smales for her helpful review of the manuscript.

The authors are indebted to Prs MA Richard, MT Leccia, L Martin, E Delaporte and Drs A Soria, A Nassif for their prompt response to the inquest.

IRB status: The study was approved by the Ile-de-France IV (Paris, France) ethics committee (IRB), n°2015/22NI.

References

- 1 Jemec GB. Clinical practice. Hidradenitis suppurativa. *N Engl J Med* 2012; **366**: 158-64.
- 2 Revuz JE, Canoui-Poitrine F, Wolkenstein P *et al*. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. *J Am Acad Dermatol* 2008; **59**: 596-601.
- 3 Zouboulis CC, Desai N, Emtestam L *et al*. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. *J Eur Acad Dermatol Venereol* 2015.
- 4 Miller I, Lynggaard CD, Lophaven S *et al*. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. *Br J Dermatol* 2011; **165**: 391-8.
- 5 Kimball AB, Kerdel F, Adams D *et al*. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. *Ann Intern Med* 2012; **157**: 846-55.
- 6 Sotiriou E, Goussi C, Lallas A *et al*. A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa. *J Drugs Dermatol* 2012; **11**: s15-20.
- 7 Grant A, Gonzalez T, Montgomery MO *et al*. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. *J Am Acad Dermatol* 2010; **62**: 205-17.
- 8 Adams DR, Yankura JA, Fogelberg AC *et al*. Treatment of hidradenitis suppurativa with etanercept injection. *Arch Dermatol* 2010; **146**: 501-4.
- 9 Canoui-Poitrine F, Le Thuaut A, Revuz JE *et al*. Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study. *J Invest Dermatol* 2013; **133**: 1506-11.
- 10 Martin-Ezquerria G, Masferrer E, Masferrer-Niubo M *et al*. Use of biological treatments in patients with hidradenitis suppurativa. *J Eur Acad Dermatol Venereol* 2015; **29**: 56-60.
- 11 Hyrich KL, Watson KD, Silman AJ *et al*. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. *Rheumatology (Oxford)* 2006; **45**: 1558-65.
- 12 Canoui-Poitrine FLTA, Revuz J, Wolkenstein P, Viallette C, Gabison G, Pouget F, Poli F, Bastuji-Garin S Smoking and hidradenitis suppurativa: risk or pronostic factor ? Results from a series of 947 patients. *J Invest Dermatol* 2012; **132**: S70-S4.
- 13 Sicilia B, Arribas F, Nerin J *et al*. Risk factors for ulcerative colitis: A population-based, case-control study in Spain. *J Crohns Colitis* 2008; **2**: 158-61.
- 14 European Medicines Agency.
http://ec.europa.eu/health/documents/communityregister/2015/20150728132555/anx_132555_fr.pdf. First medicine recommended for approval for hidradenitis suppurativa. On september, 1th 2015.

Table 1. Initial characteristics of patients with hidradenitis suppurativa (HS) who received an anti-tumor necrosis factor α (anti-TNF α) drug (n=67)

Characteristics (n=missing data)	N (%)
Women	37 (55.2)
Age, years, median (range)	38.0 (10.9–71.8)
Smoking status (n=5)	
Non-smoker	19 (30.7)
Current smoker	34 (54.8)
Ex-smoker	9 (14.5)
Body mass index, kg/m ² , median (range)	28.0 (16.7–53)
>25	48 (71.6)
>30	29 (43.4)
History of severe acne	13 (19.4)
HS phenotype *	
Classical	32 (47.8)
Follicular	14 (20.9)
Gluteal	21 (31.3)
Highest Hurley grade (n=5)	
II	16 (25.8)
III	46 (74.2)
Associated inflammatory disorder	
Inflammatory bowel disease	2 (3)
Inflammatory arthritis	11 (16.4)
Inflammatory bowel diseases or arthritis	12 (17.9)

Neutrophilic skin disease	8 (12)
Fist line anti-TNF α treatment (n=1)	
Adalumimab	7 (10.6)
Infliximab	57 (86.4)
Etanercept	2 (3)
Second line anti- TNF α treatment	12 (17.9)
Adalumimab	9/12 (52.9)
Infliximab	5/12 (29.4)
Etanercept	3/12 (17.7)
Third line anti- TNF α treatment	5 (13.4)
Adalumimab	1/5 (20)
Infliximab	1/5 (20)
Etanercept	3/5 (60)

Data are no. (%) unless indicated

*Canoui-Poittrine et al, J Invest Dermatol 2013; 133:1506-11

Table 2. Factors associated with a complete or a partial response to anti-TNF α therapy (univariate analysis, n=67)

Initial characteristics (n=missing data)	Complete response (n=8)				At least a partial response(n=39)			
	Univariate analyses		Multivariate analyses		Univariate analyses		Multivariate analyses	
	HR (95% CI) †	P value‡	HR (95% CI) †	P value‡	HR (95% CI) †	P value‡	HR (95% CI) †	P value‡
Women	0.8 (0.2–3.4)	0.75			0.7 (0.3–1.4)	0.32		
Age, years	1.0 (0.9–1.1)	0.42			1.0 (0.9–1.0)	0.92		
Current smoker	5.1 (0.9–28.3)	0.06	8.4 (1.3 – 56)	0.03	1.4 (0.7–3.1)	0.36		
Body mass index, kg/m ²								
>25	0.4 (0.08–2.1)	0.28			1.1 (0.5–2.4)	0.88		
>30	0.9 (0.2–3.9)	0.92			1.0 (0.5–2.0)	0.89		
History of severe acne	1.1 (0.1–9.5)	0.96			1.4 (0.5–3.4)	0.52		
HS phenotype (n=2)*								
Classical	1.2 (0.3–5.1)	0.81			0.8 (0.4–1.6)	0.51		
Follicular	0.4 (0.4–3.4)	0.29			1.0 (0.4–2.4)	0.95		
Gluteal	2.7 (0.4–19.4)	0.34			1.3 (0.6–3.0)	0.50		
Highest Hurley score (n=5) II (vs III)	1.3 (0.3–7.1)	0.72			0.70 (0.3–1.6)	0.40		
Associated inflammatory disorder								
Inflammatory bowel	8.4 (0.7–102.0)	0.09			1.1 (0.2–8.6)	0.90		

disease	4.0 (0.8–20.3)	0.10						
Inflammatory arthritis								
Inflammatory bowel diseases or arthritis	3.7 (0.7–18.7)	0.12	6.8 (1.2 – 40)	0.03				
Neutrophilic skin disease	0.5 (0.05–4.0)	0.49						
Anti-TNFα treatment with adalimumab as compared with etanercept or infliximab	-	-			6.6 (2.2–19.7)	0.001	6.6 (2.2–19.7)	0.001

*Canoui-Poitrine et al, J Invest Dermatol 2013; 133:1506-11

† Hazard ratios (HR) and two-sided 95% confidence intervals (CIs) were estimated by Cox's model

‡p value from Cox's model